TOP1 and peritoneum cancer: In addition, CRLX101 containing camptothecin, a DNA topoisomerase-I inhibitor, encapsulated in cyclodextrin-PEG copolymers NPs has already achieved phase I/II clinical trials in patients with rectal, ovarian, tubal, and peritoneal cancer.